Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma

Ian W. Flinn, Dana S. Thompson, Ralph V. Boccia, Gerald Miletello, Andrew Lipman, Douglas Flora, Daniel Cuevas, Steven Papish, Jesus G. Berdeja

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28%), neutropenia (30%) and lymphopenia (17%). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94% for all patients. The median follow-up was 54 months. Kaplan–Meier estimates of progression-free survival and overall survival at 36 months were 75% and 88%, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.

Original languageEnglish (US)
Pages (from-to)365-373
Number of pages9
JournalBritish Journal of Haematology
Volume180
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Non-Hodgkin's Lymphoma
Therapeutics
Lymphopenia
Bortezomib
Bendamustine Hydrochloride
Rituximab
Leukopenia
Neutropenia
Disease-Free Survival
Lymphoma
Stroke
Survival

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Flinn, I. W., Thompson, D. S., Boccia, R. V., Miletello, G., Lipman, A., Flora, D., ... Berdeja, J. G. (2018). Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. British Journal of Haematology, 180(3), 365-373. https://doi.org/10.1111/bjh.15044
Flinn, Ian W. ; Thompson, Dana S. ; Boccia, Ralph V. ; Miletello, Gerald ; Lipman, Andrew ; Flora, Douglas ; Cuevas, Daniel ; Papish, Steven ; Berdeja, Jesus G. / Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. In: British Journal of Haematology. 2018 ; Vol. 180, No. 3. pp. 365-373.
@article{5515711737e248f2bc11f1e15a7a5dba,
title = "Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma",
abstract = "This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28{\%}), neutropenia (30{\%}) and lymphopenia (17{\%}). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94{\%} for all patients. The median follow-up was 54 months. Kaplan–Meier estimates of progression-free survival and overall survival at 36 months were 75{\%} and 88{\%}, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.",
author = "Flinn, {Ian W.} and Thompson, {Dana S.} and Boccia, {Ralph V.} and Gerald Miletello and Andrew Lipman and Douglas Flora and Daniel Cuevas and Steven Papish and Berdeja, {Jesus G.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1111/bjh.15044",
language = "English (US)",
volume = "180",
pages = "365--373",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

Flinn, IW, Thompson, DS, Boccia, RV, Miletello, G, Lipman, A, Flora, D, Cuevas, D, Papish, S & Berdeja, JG 2018, 'Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma', British Journal of Haematology, vol. 180, no. 3, pp. 365-373. https://doi.org/10.1111/bjh.15044

Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma. / Flinn, Ian W.; Thompson, Dana S.; Boccia, Ralph V.; Miletello, Gerald; Lipman, Andrew; Flora, Douglas; Cuevas, Daniel; Papish, Steven; Berdeja, Jesus G.

In: British Journal of Haematology, Vol. 180, No. 3, 01.02.2018, p. 365-373.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma

AU - Flinn, Ian W.

AU - Thompson, Dana S.

AU - Boccia, Ralph V.

AU - Miletello, Gerald

AU - Lipman, Andrew

AU - Flora, Douglas

AU - Cuevas, Daniel

AU - Papish, Steven

AU - Berdeja, Jesus G.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28%), neutropenia (30%) and lymphopenia (17%). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94% for all patients. The median follow-up was 54 months. Kaplan–Meier estimates of progression-free survival and overall survival at 36 months were 75% and 88%, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.

AB - This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m2 intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2–6; bendamustine 90 mg/m2 IV on days 1 and 2; and bortezomib 1·6 mg/m2 IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28%), neutropenia (30%) and lymphopenia (17%). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94% for all patients. The median follow-up was 54 months. Kaplan–Meier estimates of progression-free survival and overall survival at 36 months were 75% and 88%, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85040860683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040860683&partnerID=8YFLogxK

U2 - 10.1111/bjh.15044

DO - 10.1111/bjh.15044

M3 - Article

C2 - 29193021

AN - SCOPUS:85040860683

VL - 180

SP - 365

EP - 373

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -